ProSomnus, Inc. (OSAPQ)

OTCMKTS: OSAPQ · Delayed Price · USD
0.0040
-0.0060 (-60.00%)
Jun 24, 2024, 4:00 PM EDT - Market open
Market Cap 64.71K
Revenue (ttm) 27.65M
Net Income (ttm) -24.10M
Shares Out 16.18M
EPS (ttm) -1.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close 0.0100
Day's Range n/a
52-Week Range 0.0040 - 0.3000
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About OSAPQ

ProSomnus, Inc. operates as a medical technology company that develops, manufactures, and markets precision intraoral medical devices for treating and managing patients with obstructive sleep apnea. The company sells its products to sleep dentists, sleep physicians, primary care providers, otolaryngologists, and other integrated healthcare service providers through a direct sales force. ProSomnus, Inc. is headquartered in Pleasanton, California. On May 7, 2024, ProSomnus, Inc., along with its affiliates, filed a voluntary petition for reorganiz... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 2016
Employees 136
Stock Exchange OTCMKTS
Ticker Symbol OSAPQ
Full Company Profile

Financial Performance

In 2023, ProSomnus's revenue was $27.65 million, an increase of 42.59% compared to the previous year's $19.39 million. Losses were -$24.10 million, 237.2% more than in 2022.

Financial numbers in USD Financial Statements

News

ProSomnus Contributes Two Scientific Abstracts for Presentation at SLEEP 2024, A Joint Meeting of the American Academy of Sleep Medicine and the Sleep Research Society

PLEASANTON, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced that it has contributed two scientific abst...

26 days ago - GlobeNewsWire

ProSomnus Announces Strong First Quarter 2024 Revenue Growth

PLEASANTON, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy, today announced results for the first quarter ended Ma...

5 weeks ago - GlobeNewsWire

ProSomnus Contributes Two Scientific Abstracts Accepted for Presentation at the 2024 American Academy of Dental Sleep Medicine Annual Meeting

PLEASANTON, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced that it has contributed two scientific abst...

6 weeks ago - GlobeNewsWire

Four Independent Scientific Abstracts at the American Academy of Dental Sleep Medicine Annual Meeting Feature ProSomnus Intraoral Medical Devices

PLEASANTON, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced that four independent scientific abstracts ...

6 weeks ago - GlobeNewsWire